The European Journal of Health Economics

, Volume 19, Issue 3, pp 471–472 | Cite as

Comment on “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”

Commentary

References

  1. 1.
    Kuhlmann, A., von der Schulenburg, J.G.: Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Eur J Health Econ 18(3), 273–292 (2017)CrossRefPubMedGoogle Scholar
  2. 2.
    Garrison Jr., L.P., Mansley, E.C., Abbott 3rd, T.A., Bresnahan, B.W., Hay, J.W., Smeeding, J.: Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective. The ISPOR Drug Cost Task Force report–Part II. Value Health 13(1), 8–13 (2010)CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Frankfurt School of Finance and ManagementFrankfurt am MainGermany

Personalised recommendations